Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia

Cancer Research

Volumn 56, Issue 19, 1996, Pages 4444-4452

  Cesano, Alessandra ^a   Visonneau, Sophie ^a   Pasquini, Susanna ^a   Rovera, Giovanni ^a   Santoli, Daniela ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENCY; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA CELL; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBODIES, NEOPLASM; APOPTOSIS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; DNA REPLICATION; HUMANS; IMMUNOCOMPETENCE; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, PRE-B-CELL; MICE; NEOPLASM TRANSPLANTATION; RADIATION CHIMERA; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029782425     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rosenberg, S A , Lotze, M T , Muul, L M , Leitman, S , Chang, A. E , Ettinghausen, S E , Matori, Y. L., Skibber, J. M., Shiloni, E , Vetto, J T, Seipp, C. A , Simpson, C , and Reichert, C. M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer N. Engl J. Med., 313: 1485-1492, 1985.
2. Rosenberg, S. A., Lotze, M T., Yang, J. C , Aebersold, P M., Linehan, W. M., Seipp, C A., and White, D. E Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Ann. Surg., 210: 474-484, 1989
3. Rosenberg, S A , Packard, B S , Aebersold, P. M., Solomon, D , Topalian, S L , Toy, S. T , Simon, R., Lotze, M. T., Yang, J C., Seipp, C A , Simpson, C., Carter C., Bock, S., Schwartzentruber, D , Wei, J. P., and White, D. E. Use of tumor-infiltrating lymphocytes and interleukin-2 in immunotherapy of patients with metastatic melanoma. N Engl J. Med. 319, 1676-1680, 1988.
4. Whittington, R., and Faulds, D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer Drugs, 46: 446-513, 1993.
5. O'Connor, R., Cesano, A , Lange, B , Finan, J , Nowell, P C , Clark, S C., Raimondi, S C., Rovera, G., and Santoli, D. Growth factor requirements of childhood acute T lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood, 77 1534-1545, 1991
6. Cesano, A., and Santoli, D. Two unique human leukemic T-cell lines endowed with stable cytotoxic function and different spectrum of target reactivity: analysis and modulation of their lytic mechanisms. In Vitro Cell Dev. Biol., 28A: 648-656, 1992.
7. Cesano, A , and Santoli, D. Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α and interferon-γ in two human cytotoxic leukemic T cell lines. In Vitro Cell Dev Biol., 28A: 657-662, 1992
8. Cesano, A , Visonneau, S., Clark, S C., and Santoli, D. Cellular and molecular mechanisms of activation of MHC non-restricted cytotoxic cells by IL-2. J Immunol., 151: 2943-2957, 1993.
9. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., Rovera, G , and Santoli, D. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach J. Clin Invest., 94, 1076-1084, 1994.
10. Cesano, A , Visonneau, S., and Santoli, D Treatment of experimental glioblastoma with a human MHC non-restricted cytotoxic T-cell line. Cancer Res., 55: 96-101, 1995
11. Cesano, A , Pierson, G., Visonneau, S., Migliaccio, A. R , and Santoli, D. Use of a tethally irradiated major histocompatibility complex non-restricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets. Blood, 87, 393-403, 1996.
12. Cesano, A , Visonneau, S , Jeglum, K A., Owen, J., Wilkinson, K., Carner, K , Reese, L , and Santoli. D Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res., 56: 3021-3029, 1996.
13. Paige, C J., Kincade, P W , and Ralph, P. Murine B cell leukemia line with inducible surface immunoglobulin expression. J Immunol., 121: 641-647, 1978
14. Yamada, M., Hudson, S , Tournay, O , Bittenbender, S , Shane, S. S., Lange, B , Tsujimoto, Y., Caton, A. J., and Rovera, G Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc. Natl. Acad. Sci. USA, 86 5123-5127, 1989.
15. Cesano, A., Hoxie, J A , Lange, B , Nowell, P C., Bishop, J , and Santoli, D. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene, 7, 827-836, 1992.
16. Gavrieh, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell. Biol., 119: 493-501, 1992.
17. Sellins, K. S , and Cohen, J J. Cytotoxic T lymphocytes induce different types of DNA damage in target cells of different origins. J. Immunol , 147: 795-803, 1991
18. Matzinger, P The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods, 145: 185-192, 1991.
19. Mule, J J., Shu, S. Y., Schwarz, S. L , and Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (Washington DC), 225, 1487-1489, 1984.
20. Papa, M. Z., Mule, J. J , and Rosenberg, S A. Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types Cancer Res., 46: 4973-4978, 1986
21. Ettinghausen, S E., Lipford, E. H , Mule, J J , and Rosenberg, S A Recombinant interleukin-2 stimulates in vitro proliferation of adoptively transferred lymphokine-activated killer (LAK) cells J. Immunol., 135: 3623-3635, 1985.
22. Ettinghausen, S. E., Puri, R. K., and Rosenberg, S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice J Natl. Cancer Inst., 80 177-188, 1988.